Lynne Lederman, PhD

A small, early trial demonstrated that a combination of Imlygic and Keytruda can have clinical benefit for patients with advanced melanoma.

While inherited factors do play a role in many people getting colorectal cancer, researchers are still unsure how to identify these mutations.